Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer

  • bioRxiv. 2024 Mar 2:2024.02.29.582768. doi: 10.1101/2024.02.29.582768.
Tongchen He  1  2  3  4 ,  Caleb Cheng  1  5  6  4 ,  Yuanyuan Qiao  1  2  7 ,  Hanbyul Cho  1  2 ,  Eleanor Young  1  2 ,  Rahul Mannan  1  2 ,  Somnath Mahapatra  1  2 ,  Stephanie J Miner  1  2 ,  Yang Zheng  1  2 ,  NamHoon Kim  1 ,  Victoria Z Zeng  1 ,  Jasmine P Wisniewski  1 ,  Siyu Hou  8 ,  Bailey Jackson  1 ,  Xuhong Cao  1  2  9 ,  Fengyun Su  1  2 ,  Rui Wang  1  2 ,  Yu Chang  1  2 ,  Bilash Kuila  10 ,  Subhendu Mukherjee  10 ,  Sandeep Dukare  10 ,  Kiran B Aithal  10 ,  Samiulla D S  10 ,  Chandrasekhar Abbineni  10 ,  Costas A Lyssiotis  7  11  12 ,  Abhijit Parolia  1  2  7 ,  Lanbo Xiao  1  2  7 ,  Arul M Chinnaiyan  1  2  7  9  13
Affiliations
  • 1. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
  • 2. Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
  • 3. Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • 4. These authors contributed equally.
  • 5. Medical Scientist Training Program, University of Michigan, Ann Arbor, MI, USA.
  • 6. Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI, USA.
  • 7. Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
  • 8. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
  • 9. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA.
  • 10. Aurigene Oncology Limited, Bangalore, India.
  • 11. Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.
  • 12. Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.
  • 13. Department of Urology, University of Michigan, Ann Arbor, MI, USA.
PMID: 38464081 DOI: 10.1101/2024.02.29.582768
Abstract

Mammalian switch/sucrose non-fermentable (mSWI/SNF) ATPase degraders have been shown to be effective in enhancer-driven cancers by functioning to impede oncogenic transcription factor chromatin accessibility. Here, we developed AU-24118, a first-in-class, orally bioavailable proteolysis targeting chimera (PROTAC) degrader of mSWI/SNF ATPases (SMARCA2 and SMARCA4) and PBRM1. AU-24118 demonstrated tumor regression in a model of castration-resistant prostate Cancer (CRPC) which was further enhanced with combination enzalutamide treatment, a standard of care Androgen Receptor (AR) antagonist used in CRPC patients. Importantly, AU-24118 exhibited favorable pharmacokinetic profiles in preclinical analyses in mice and rats, and further toxicity testing in mice showed a favorable safety profile. As acquired resistance is common with targeted Cancer therapeutics, experiments were designed to explore potential mechanisms of resistance that may arise with long-term mSWI/SNF ATPase PROTAC treatment. Prostate Cancer cell lines exposed to long-term treatment with high doses of a mSWI/SNF ATPase degrader developed SMARCA4 bromodomain mutations and ABCB1 overexpression as acquired mechanisms of resistance. Intriguingly, while SMARCA4 mutations provided specific resistance to mSWI/SNF degraders, ABCB1 overexpression provided broader resistance to Other potent PROTAC degraders targeting bromodomain-containing protein 4 (BRD4) and AR. The ABCB1 inhibitor, zosuquidar, reversed resistance to all three PROTAC degraders tested. Combined, these findings position mSWI/SNF degraders for clinical translation for patients with enhancer-driven cancers and define strategies to overcome resistance mechanisms that may arise.

Keywords
ABCB1; SMARCA2 and SMARCA4; mSWI/SNF; proteolysis targeting chimera (PROTAC).
Products